These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22948884)

  • 21. Uncommon vancomycin-induced side effects.
    Rocha JL; Kondo W; Baptista MI; Da Cunha CA; Martins LT
    Braz J Infect Dis; 2002 Aug; 6(4):196-200. PubMed ID: 12204187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study.
    Huwyler T; Lenggenhager L; Abbas M; Ing Lorenzini K; Hughes S; Huttner B; Karmime A; Uçkay I; von Dach E; Lescuyer P; Harbarth S; Huttner A
    Clin Microbiol Infect; 2017 Jul; 23(7):454-459. PubMed ID: 28111294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients.
    Chaudhary M; Shrivastava SM; Varughese L; Sehgal R
    Curr Clin Pharmacol; 2008 May; 3(2):118-22. PubMed ID: 18700304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefepime-associated thrombocytopenia in a critically ill patient.
    Lim PP; Chong CP; Aziz NA
    Int J Clin Pharm; 2011 Dec; 33(6):902-4. PubMed ID: 21986835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis.
    Han EE; Beringer PM; Falck P; Louie S; Rao P; Shapiro B; Gill M
    J Antimicrob Chemother; 2006 May; 57(5):1017-9. PubMed ID: 16533828
    [No Abstract]   [Full Text] [Related]  

  • 27. Cefepime-Induced Neurotoxicity Despite Dose Adjustment for Renal Disease: A Brief Report and Review of the Literature.
    Lindsay H; Gruner S; Brackett J
    J Pediatric Infect Dis Soc; 2017 Jun; 6(2):199-201. PubMed ID: 27147713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion.
    Berti AD; Hutson PR; Schulz LT; Webb AP; Rose WE
    Am J Health Syst Pharm; 2015 Mar; 72(5):390-5. PubMed ID: 25694414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Intravenous Vancomycin and Cefepime in Preventing Endophthalmitis After Open Globe Injury.
    Huang JM; Pansick AD; Blomquist PH
    J Ocul Pharmacol Ther; 2016 Sep; 32(7):437-41. PubMed ID: 27414817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vancomycin-induced red man syndrome.
    Levy M; Koren G; Dupuis L; Read SE
    Pediatrics; 1990 Oct; 86(4):572-80. PubMed ID: 2216623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".
    Sahai J; Healy DP; Shelton MJ; Miller JS; Ruberg SJ; Polk R
    Antimicrob Agents Chemother; 1990 May; 34(5):765-9. PubMed ID: 1694421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin-induced red man syndrome presentation in a preterm infant.
    Martini S; Alessandroni R; Arcuri S; Faldella G
    Pediatr Dermatol; 2018 Nov; 35(6):e408-e409. PubMed ID: 30168173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corrado ML
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible coma secondary to cefepime neurotoxicity.
    Abanades S; Nolla J; Rodríguez-Campello A; Pedro C; Valls A; Farré M
    Ann Pharmacother; 2004 Apr; 38(4):606-8. PubMed ID: 14982986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion.
    Garrelts JC; Wagner DJ
    Ann Pharmacother; 1999 Dec; 33(12):1258-61. PubMed ID: 10630824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefepime and mortality: a real issue?
    Mebis J; Goossens H; Berneman ZN
    Scand J Infect Dis; 2010 Jul; 42(6-7):545-8. PubMed ID: 20144128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefepime induced acute interstitial nephritis--a case report.
    Mac K; Chavada R; Paull S; Howlin K; Wong J
    BMC Nephrol; 2015 Feb; 16():15. PubMed ID: 25886295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach.
    Bernard E; Breilh D; Bru JP; Chiche D; Dujardin I; Garraffo R; Goldstein F; Lavrard I; Potel G
    Clin Microbiol Infect; 2003 May; 9(5):339-48. PubMed ID: 12848746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
    Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
    Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.